Author

J. R. Jett

Observed names: J. Jett, J.R. Jett, JR Jett, Jett, JR

Observed institutions: Roswell Park Comprehensive Cancer Center, Loyola University Medical Center, Sunnybrook Health Science Centre, Mayo Clinic, North Central Cancer Treatment Group, The University of Kansas Health System, University of Colorado Health, Iowa Oncology Research Association, Michigan Cancer Research Consortium, Mayo Clinic in Arizona, University of Kansas Medical Center, Illinois CancerCare, Duluth Clinic, University of California, Davis

OpenAlex ID: A5110029856

Lung Cancer: Current Concepts and Prospects

1983 · J. R. Jett, D. A. Cortese, et al. · CA A Cancer Journal for Clinicians · 45

S0124: A randomized phase III trial comparing irinotecan/cisplatin (IP) with etoposide/cisplatin (EP) in patients (pts) with previously untreated extensive stage small cell lung cancer (E-SCLC)

2008 · R. B. Natale, P. N. Lara, et al. · Journal of Clinical Oncology · 44

Updated analysis of SWOG 0023: A randomized phase III trial of gefitinib versus placebo maintenance after definitive chemoradiation followed by docetaxel in patients with locally advanced stage III non-small cell lung cancer

2007 · K. Kelly, K. Chansky, et al. · Journal of Clinical Oncology · 40

38 Topotecan and paclitaxel in extensive stage small cell lung cancer (ED-SCLC) patients without prior therapy

1997 · J.R. Jett, R. Day, et al. · Lung Cancer · 21

Results of a Phase I Trial of Concurrent Chemotherapy and Escalating Doses of Radiation for Unresectable Non-Small Cell Lung Cancer

2005 · S.E. Schild, W.L. McGinnis, et al. · International Journal of Radiation Oncology*Biology*Physics · 20

The value of combined modality therapy in elderly patients with stage III non-small cell lung cancer (NSCLC)

2007 · S. E. Schild, S. J. Mandrekar, et al. · Journal of Clinical Oncology · 5

Phase II trial of pemetrexed (P) and carboplatin (C) in previously untreated extensive stage disease small cell lung cancer (ED-SCLC): A NCCTG Study

2008 · J. R. Jett, A. M. Bernath, et al. · Journal of Clinical Oncology · 4

Is there a role for adjuvant therapy for resected non-small cell lung cancer?

1999 · J. R. Jett · Thorax · 2

Cost-effectiveness of an autoantibody test (AABT) as an aid to diagnosis of lung cancer.

2010 · D. Weycker, J. R. Jett, et al. · Journal of Clinical Oncology · 1

Comparison of progression-free survival (PFS) and tumor response as endpoints for predicting overall survival (OS) in untreated extensive-stage small cell lung cancer (ED-SCLC): Findings based on North Central Cancer Treatment Group (NCCTG) trials

2009 · N. R. Foster, Y. Qi, et al. · Journal of Clinical Oncology · 1

Prognostic importance of performance status (PS) in small cell lung cancer (SCLC): A North Central Cancer Treatment Group (NCCTG) investigation

2008 · N. R. Foster, S. J. Mandrekar, et al. · Journal of Clinical Oncology · 1

Impact of the algorithm for declaring exact progression date on progression-free survival (PFS) estimates in advanced lung cancer clinical trials.

2010 · S. J. Mandrekar, S. L. Hillman, et al. · Journal of Clinical Oncology

Value of a serum proteomic signature in the non-invasive evaluation of lung nodules.

2010 · C. V. Pecot, X. Zhang, et al. · Journal of Clinical Oncology

Tumor response and progression-free survival (PFS) as potential surrogate endpoints for overall survival (OS) in extensive-stage small cell lung cancer (ES-SCLC): Findings based on North Central Cancer Treatment Group (NCCTG) trials.

2010 · N. R. Foster, Y. Qi, et al. · Journal of Clinical Oncology

Screening for lung cancer

2009 · D.E. Midthun, J.R. Jett · European Respiratory Society eBooks

Are Airflow Obstruction and Radiographic Emphysema Risk Factors for Lung Cancer?.

2009 · F Maldonado, BJ Batholmai, et al.

Works count: 17

Citation count: 185

H-index: 5

I10-index: 5